By Josh White
Date: Wednesday 17 Sep 2025
(Sharecast News) - Fusion Antibodies reported further validation of its OptiMAL discovery platform on Wednesday, saying its collaboration with the US National Cancer Institute had confirmed antibody binders to three cancer targets and that the NCI had asked to extend its use of the technology beyond the current agreement, which runs to November 2025.
By Iain Gilbert
Date: Wednesday 27 Aug 2025
(Sharecast News) - Pre-clinical antibody discovery specialists Fusion Antibodies said on Wednesday that it has been selected for three follow-on projects to its existing stable Cell Line Development project.
By Josh White
Date: Friday 31 Jan 2025
(Sharecast News) - Fusion Antibodies announced on Friday that its OptiMAL validation project with the US National Cancer Institute (NCI) was progressing as planned.
Currency | UK Pounds |
Share Price | 13.75p |
Change Today | 0.25p |
% Change | 1.85 % |
52 Week High | 18.75p |
52 Week Low | 4.00p |
Volume | 559,686 |
Shares Issued | 113.66m |
Market Cap | £15.63m |
RiskGrade | 464 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:28 | 4 @ 14.00p |
16:27 | 7,204 @ 13.88p |
16:23 | 4 @ 14.00p |
16:14 | 4 @ 14.00p |
16:10 | 51 @ 13.50p |
Chair | Simon Gordon Douglas |
CEO | Adrian Kinkaid |
You are here: research